{
Bio-Rad Laboratories, Inc.

Companies

}
global clinical biomarkers market projected to reach 47 billion by 2031
The global clinical biomarkers market, valued at $25.02 billion in 2023, is projected to reach $47.25 billion by 2031, growing at a CAGR of 8.54%. This growth is driven by rising cancer cases and advancements in diagnostic technologies, despite challenges like high costs and reimbursement issues. Key players include Roche, Abbott, and Johnson & Johnson, with significant developments in biomarker testing for various diseases.
openPR.com
Eurofins Scientific S.E. A PerkinElmer Inc Johnson & Johnson Services Inc. Bio-Rad Laboratories, Inc. Qiagen N.V. Merck KGaA Thermo Fisher Scientific Inc. General Electric Co Siemens Healthineers AG Agilent Technologies, Inc. F. Hoffmann-La Roche Ltd. USA Show more
Healthcare, Market Report
08:45 16.12.2024
global growth trends in the crispr and cas gene market to 2033
The global CRISPR and Cas gene market reached approximately $3.3 billion in 2023, growing at a CAGR of 20.38% since 2018. It is projected to expand to $8.8 billion by 2028 and $24.6 billion by 2033, driven by advancements in cancer therapeutics and gene therapy research. North America leads the market, accounting for 45.3% of the total value in 2023.
GlobeNewswire News Room
United States Dollar Bayer AG Bio-Rad Laboratories, Inc. Pluristem Therapeutics Inc. Genscript Biotech Corporation AstraZeneca PLC Qiagen N.V. Hologic, Inc. Cellectis S.A. Takara Bio Inc. Vertex Pharmaceuticals Inc Thermo Fisher Scientific Inc. Sigma-Aldrich Co. LLC Regeneron Pharmaceuticals Inc Editas Medicine Inc IND GBR ESP CAN AUS ITA IDN JPN BRA DEU FRA RUS KOR CHN USA Show more
Technology & Innovation, Market Report
15:27 13.12.2024
global healthcare market trends forecast significant growth through 2034
In January 2023, a significant acquisition occurred as Verinata Health, Inc. was purchased for $1.9 billion. The market for preterm birth diagnostic kits features key players like Qiagen and Hologic Inc., with products including ffN and PAMG-1 tests, serving hospitals and diagnostic labs across various global regions. The preterm birth prevention market is projected to grow from $1.70 billion in 2024 to over $4.49 billion by 2034, reflecting a robust CAGR of 10.2%.
GlobeNewswire News Room
United States Dollar Illumina, Inc. Bio-Rad Laboratories, Inc. Nanjing Liming Biological Preparations Co., Ltd. Qiagen N.V. Hologic, Inc. USA Bio-Rad Laboratories Invitae Sabyasachi Ghosh Illumina Inc. Natera Inc. Show more
Healthcare, Market Report
15:31 13.11.2024
global immunoassay market growth driven by innovative technologies and rising demand
The global immunoassay market is projected to grow significantly, driven by advancements in enzyme immunoassays, which held over 58.2% market share in 2022. The infectious disease testing segment is expected to expand at a CAGR of 5.6%, fueled by rising global incidences of diseases like HIV and hepatitis. North America leads the market with over 36.2% of revenues, supported by advanced healthcare infrastructure and a high prevalence of chronic diseases.
Spherical Insights
United States Dollar SIEMENS HEALTHINEERS BioMerieux SA Abbott Laboratories Danaher Company Quidel Company Ortho-Clinical Diagnostics Inc. Sysmex Company Bio-Rad Laboratories, Inc. Becton, Dickinson and Company F. Hoffmann-La Roche AG Thermo Fisher Scientific Inc. USA CAN MEX DEU GBR FRA ITA ESP RUS CHN JPN IND KOR AUS BRA ARG ARE SAU QAT ZAF Show more
Healthcare, Market Report
09:51 08.11.2024
bio-rad laboratories receives buy recommendation from ubs amid strong market presence
Bio-Rad Laboratories, Inc. focuses on developing, manufacturing, and marketing products for life science research, clinical diagnostics, and analytical chemistry. Its net sales are primarily derived from clinical diagnostic tests (55.8%) and biological research reagents and instruments (44.1%). The company operates 16 production sites globally, with significant sales in the United States (42%), Europe (30.7%), and Asia (21.1%).
de.marketscreener.com
Euro United States Dollar Bio-Rad Laboratories, Inc. DEU POL SGP USA GBR CHN CHE FRA Show more
TradFi, Market Report
00:55 01.11.2024
bio-rad laboratories receives buy recommendation from ubs amid strong market presence
Bio-Rad Laboratories, Inc. focuses on developing, manufacturing, and marketing products for life science research, clinical diagnostics, and analytical chemistry. Its net sales are primarily derived from clinical diagnostic tests (55.8%) and biological research reagents and instruments (44.1%). The company operates 16 production sites globally, with significant sales in the United States (42%), Europe (30.7%), and Asia (21.1%).
MarketScreener
Euro United States Dollar Bio-Rad Laboratories, Inc. DEU POL SGP USA GBR CHN CHE FRA Show more
TradFi, Market Report
00:55 01.11.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Market Sentiment Analysis Banking Regulations Central Bank Actions Corporate Responsibility & ESG Decentralized Finance (DeFi) Innovations Tokenomics and Crypto Economics Cryptocurrency & Blockchain Regulations Mergers & Acquisitions Cryptocurrency Developments Blockchain Technology Adoption Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Cryptocurrency Regulations Emerging Startups SEC & Financial Compliance Inflation Rates & CPI Data Banking & Investment Regulations
Countries:
USA CHE GBR DEU ARE HKG AUS JPN IND CHN CAN SGP DNK AUT LIE KOR NGA FIN COL VGB
Companies:
Credit Suisse Real Estate Fund Siat Coinbase Global, Inc. BlackRock, Inc. Solana USD Ripples USD Ethereum USD Apple Inc. Tesla, Inc. Fidelity Contrafund Cardano USD NVIDIA Corporation Grayscale Litecoin Trust Chainlink USD Tether USDt CNY Google Inc. Amazon.com, Inc. MicroStrategy Inc Franklin Templeton - Franklin M End Federal Reserve USD MicroStrategy Incorporated
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Indian Rupee Canadian Dollar Mozambican Metical British Pound Sterling Norwegian Krone Mongolian Tögrög Colombian Peso Singapore Dollar
People:
Donald Trump Ali Martinez Elon Musk Karin Keller-Sutter Jerome Powell Ueli Maurer Michael J. Saylor Gary Gensler Thomas Jordan Colm Kelleher Alan Santana Paul Atkins Joe Rogan Martin Schlegel Isabelle Chassot Mario Nawfal Paolo Ardoino Sergio Ermotti Dana White Joe Biden

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.